First Author, CNIO triple-therapy study; Co-founder, Vega Oncotargets
Appears in 1 story
Named in PNAS retraction for undisclosed financial stake in Vega Oncotargets; paper resubmitted through standard peer review
On May 31, Revolution Medicines presented the full Phase 3 RASolute 302 dataset at the ASCO plenary in Chicago, simultaneously published in the New England Journal of Medicine. Daraxonrasib cut the risk of death by 60%. The drug produced a 33.2% objective response rate versus 11.8% on chemotherapy and nearly halved the rate at which patients' pain worsened.
Updated Jun 8
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
